LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes
Movement Disorders · 2023-04 · 38 (4) · 682-688
DOI: 10.1002/mds.29336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 18.02.2023. Verfasst von Andrea Mancini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Dementia, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, Parkinsonian Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The alteration of leucine‐rich repeat kinase 2 (LRRK2) kinase activity is thought to be involved in Parkinson's disease (PD) pathogenesis beyond familiar cases, and LRRK2 inhibitors are currently under investigation. Preliminary data suggest a relationship between LRRK2 alteration and cognitive impairment in PD.
Objective
To investigate cerebrospinal fluid (CSF) LRRK2 levels in PD and other parkinsonian disorders, also correlating them with cognitive impairment.
Methods
In this study, we retrospectively investigated by means of a novel highly sensitive immunoassay the levels of total and phosphorylated (pS1292) LRRK2 in CSF of cognitively unimpaired PD (n = 55), PD with mild cognitive impairment (n = 49), PD with dementia (n = 18), dementia with Lewy bodies (n = 12), atypical parkinsonian syndromes (n = 35), and neurological controls (n = 30).
Results
Total and pS1292 LRRK2 levels were significantly higher in PD with dementia with respect to PD with mild cognitive impairment and PD, and also showed a correlation with cognitive performances.
Conclusions
The tested immunoassay may represent a reliable method for assessing CSF LRRK2 levels. The results appear to confirm an association of LRRK2 alteration with cognitive impairment in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- ADx NeuroSciences NV, Gent, Belgium.
- Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
ORCID-Profile: Andrea Mancini, Federico Paolini Paoletti
Zitieren
APA
Mancini, A., Stoops, E., Demeyer, L., Bellomo, G., Paolini Paoletti, F., Gaetani, L., Di Filippo, M., & Parnetti, L. (2023). LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes. Movement Disorders, 38(4), 682-688. https://doi.org/10.1002/mds.29336
Vancouver
Mancini A, Stoops E, Demeyer L, Bellomo G, Paolini Paoletti F, Gaetani L, et al. LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes. Movement Disorders. 2023;38(4):682-688. doi:10.1002/mds.29336
BibTeX
@article{Mancini2023,
author = {Mancini, Andrea and Stoops, Erik and Demeyer, Leentje and Bellomo, Giovanni and Paolini Paoletti, Federico and Gaetani, Lorenzo and Di Filippo, Massimiliano and Parnetti, Lucilla},
title = {LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes},
journal = {Movement Disorders},
year = {2023},
volume = {38},
number = {4},
pages = {682--688},
doi = {10.1002/mds.29336}
}
EUVIMED